Cargando…

Reduced replication but increased interferon resistance of SARS-CoV-2 Omicron BA.1

The IFN system constitutes a powerful antiviral defense machinery. Consequently, effective IFN responses protect against severe COVID-19 and exogenous IFNs inhibit SARS-CoV-2 in vitro. However, emerging SARS-CoV-2 variants of concern (VOCs) may have evolved reduced IFN sensitivity. Here, we determin...

Descripción completa

Detalles Bibliográficos
Autores principales: Nchioua, Rayhane, Schundner, Annika, Klute, Susanne, Koepke, Lennart, Hirschenberger, Maximilian, Noettger, Sabrina, Fois, Giorgio, Zech, Fabian, Graf, Alexander, Krebs, Stefan, Braubach, Peter, Blum, Helmut, Stenger, Steffen, Kmiec, Dorota, Frick, Manfred, Kirchhoff, Frank, Sparrer, Konstantin MJ
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Life Science Alliance LLC 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053418/
https://www.ncbi.nlm.nih.gov/pubmed/36977594
http://dx.doi.org/10.26508/lsa.202201745
_version_ 1785015409361027072
author Nchioua, Rayhane
Schundner, Annika
Klute, Susanne
Koepke, Lennart
Hirschenberger, Maximilian
Noettger, Sabrina
Fois, Giorgio
Zech, Fabian
Graf, Alexander
Krebs, Stefan
Braubach, Peter
Blum, Helmut
Stenger, Steffen
Kmiec, Dorota
Frick, Manfred
Kirchhoff, Frank
Sparrer, Konstantin MJ
author_facet Nchioua, Rayhane
Schundner, Annika
Klute, Susanne
Koepke, Lennart
Hirschenberger, Maximilian
Noettger, Sabrina
Fois, Giorgio
Zech, Fabian
Graf, Alexander
Krebs, Stefan
Braubach, Peter
Blum, Helmut
Stenger, Steffen
Kmiec, Dorota
Frick, Manfred
Kirchhoff, Frank
Sparrer, Konstantin MJ
author_sort Nchioua, Rayhane
collection PubMed
description The IFN system constitutes a powerful antiviral defense machinery. Consequently, effective IFN responses protect against severe COVID-19 and exogenous IFNs inhibit SARS-CoV-2 in vitro. However, emerging SARS-CoV-2 variants of concern (VOCs) may have evolved reduced IFN sensitivity. Here, we determined differences in replication and IFN susceptibility of an early SARS-CoV-2 isolate (NL-02-2020) and the Alpha, Beta, Gamma, Delta, and Omicron VOCs in Calu-3 cells, iPSC-derived alveolar type-II cells (iAT2) and air–liquid interface (ALI) cultures of primary human airway epithelial cells. Our data show that Alpha, Beta, and Gamma replicated to similar levels as NL-02-2020. In comparison, Delta consistently yielded higher viral RNA levels, whereas Omicron was attenuated. All viruses were inhibited by type-I, -II, and -III IFNs, albeit to varying extend. Overall, Alpha was slightly less sensitive to IFNs than NL-02-2020, whereas Beta, Gamma, and Delta remained fully sensitive. Strikingly, Omicron BA.1 was least restricted by exogenous IFNs in all cell models. Our results suggest that enhanced innate immune evasion rather than higher replication capacity contributed to the effective spread of Omicron BA.1.
format Online
Article
Text
id pubmed-10053418
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Life Science Alliance LLC
record_format MEDLINE/PubMed
spelling pubmed-100534182023-03-30 Reduced replication but increased interferon resistance of SARS-CoV-2 Omicron BA.1 Nchioua, Rayhane Schundner, Annika Klute, Susanne Koepke, Lennart Hirschenberger, Maximilian Noettger, Sabrina Fois, Giorgio Zech, Fabian Graf, Alexander Krebs, Stefan Braubach, Peter Blum, Helmut Stenger, Steffen Kmiec, Dorota Frick, Manfred Kirchhoff, Frank Sparrer, Konstantin MJ Life Sci Alliance Research Articles The IFN system constitutes a powerful antiviral defense machinery. Consequently, effective IFN responses protect against severe COVID-19 and exogenous IFNs inhibit SARS-CoV-2 in vitro. However, emerging SARS-CoV-2 variants of concern (VOCs) may have evolved reduced IFN sensitivity. Here, we determined differences in replication and IFN susceptibility of an early SARS-CoV-2 isolate (NL-02-2020) and the Alpha, Beta, Gamma, Delta, and Omicron VOCs in Calu-3 cells, iPSC-derived alveolar type-II cells (iAT2) and air–liquid interface (ALI) cultures of primary human airway epithelial cells. Our data show that Alpha, Beta, and Gamma replicated to similar levels as NL-02-2020. In comparison, Delta consistently yielded higher viral RNA levels, whereas Omicron was attenuated. All viruses were inhibited by type-I, -II, and -III IFNs, albeit to varying extend. Overall, Alpha was slightly less sensitive to IFNs than NL-02-2020, whereas Beta, Gamma, and Delta remained fully sensitive. Strikingly, Omicron BA.1 was least restricted by exogenous IFNs in all cell models. Our results suggest that enhanced innate immune evasion rather than higher replication capacity contributed to the effective spread of Omicron BA.1. Life Science Alliance LLC 2023-03-28 /pmc/articles/PMC10053418/ /pubmed/36977594 http://dx.doi.org/10.26508/lsa.202201745 Text en © 2023 Nchioua et al. https://creativecommons.org/licenses/by/4.0/This article is available under a Creative Commons License (Attribution 4.0 International, as described at https://creativecommons.org/licenses/by/4.0/).
spellingShingle Research Articles
Nchioua, Rayhane
Schundner, Annika
Klute, Susanne
Koepke, Lennart
Hirschenberger, Maximilian
Noettger, Sabrina
Fois, Giorgio
Zech, Fabian
Graf, Alexander
Krebs, Stefan
Braubach, Peter
Blum, Helmut
Stenger, Steffen
Kmiec, Dorota
Frick, Manfred
Kirchhoff, Frank
Sparrer, Konstantin MJ
Reduced replication but increased interferon resistance of SARS-CoV-2 Omicron BA.1
title Reduced replication but increased interferon resistance of SARS-CoV-2 Omicron BA.1
title_full Reduced replication but increased interferon resistance of SARS-CoV-2 Omicron BA.1
title_fullStr Reduced replication but increased interferon resistance of SARS-CoV-2 Omicron BA.1
title_full_unstemmed Reduced replication but increased interferon resistance of SARS-CoV-2 Omicron BA.1
title_short Reduced replication but increased interferon resistance of SARS-CoV-2 Omicron BA.1
title_sort reduced replication but increased interferon resistance of sars-cov-2 omicron ba.1
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053418/
https://www.ncbi.nlm.nih.gov/pubmed/36977594
http://dx.doi.org/10.26508/lsa.202201745
work_keys_str_mv AT nchiouarayhane reducedreplicationbutincreasedinterferonresistanceofsarscov2omicronba1
AT schundnerannika reducedreplicationbutincreasedinterferonresistanceofsarscov2omicronba1
AT klutesusanne reducedreplicationbutincreasedinterferonresistanceofsarscov2omicronba1
AT koepkelennart reducedreplicationbutincreasedinterferonresistanceofsarscov2omicronba1
AT hirschenbergermaximilian reducedreplicationbutincreasedinterferonresistanceofsarscov2omicronba1
AT noettgersabrina reducedreplicationbutincreasedinterferonresistanceofsarscov2omicronba1
AT foisgiorgio reducedreplicationbutincreasedinterferonresistanceofsarscov2omicronba1
AT zechfabian reducedreplicationbutincreasedinterferonresistanceofsarscov2omicronba1
AT grafalexander reducedreplicationbutincreasedinterferonresistanceofsarscov2omicronba1
AT krebsstefan reducedreplicationbutincreasedinterferonresistanceofsarscov2omicronba1
AT braubachpeter reducedreplicationbutincreasedinterferonresistanceofsarscov2omicronba1
AT blumhelmut reducedreplicationbutincreasedinterferonresistanceofsarscov2omicronba1
AT stengersteffen reducedreplicationbutincreasedinterferonresistanceofsarscov2omicronba1
AT kmiecdorota reducedreplicationbutincreasedinterferonresistanceofsarscov2omicronba1
AT frickmanfred reducedreplicationbutincreasedinterferonresistanceofsarscov2omicronba1
AT kirchhofffrank reducedreplicationbutincreasedinterferonresistanceofsarscov2omicronba1
AT sparrerkonstantinmj reducedreplicationbutincreasedinterferonresistanceofsarscov2omicronba1